bioXXmed

bioXXmed AG, formerly known as CO.DON AG, is a German biopharmaceutical company specializing in the development and marketing of autologous cell therapies for the repair of cartilage defects. The company's primary product, Spherox, is an advanced therapy medicinal product (ATMP) used for the treatment of articular cartilage defects in the knee. Following a period of financial restructuring and insolvency proceedings in 2022-2023, the company rebranded as bioXXmed to focus on the commercialization of its regenerative medicine portfolio. The company operates primarily in the European market, providing personalized treatment options that utilize a patient's own cells to restore joint function.